SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
CART-ddBCMA er nú rannsökuð í 2. stigs lykilrannsókn, CART-ddBCMA er T-frumumeðferð Arcellx sem notar nýtt tilbúið bindiefni fyrirtækisins, D-lénið. Kite og Arcellx munu sameiginlega koma og markaðssetja CART-ddBCMA eignina í Bandaríkjunum og Kite mun markaðssetja vöruna utan Bandaríkjanna
C-T-frumumeðferð er meðal byltingarkennda meðferðar við ákveðnum tegundum blóðkrabbameins. Það eru meira en 750 í gangi klínískar rannsóknir in CAR T-Cell meðferð í Kína um þessar mundir. Sjúklingar sem vilja skrá sig geta haft samband CancerFax hjálparlína sjúklinga á WhatsApp + 91 96 1588 1588 eða sendu tölvupóst til info@cancerfax.com.
Um Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory mörg mergæxli (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk mergmisþroska heilkenni, initiated in the fourth quarter of 2022.
Um Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Um Gilead Sciences
Gilead Sciences, Inc. er líflyfjafyrirtæki sem hefur stundað og náð byltingum í læknisfræði í meira en þrjá áratugi, með það að markmiði að skapa heilbrigðari heim fyrir allt fólk. Fyrirtækið hefur skuldbundið sig til að koma á framfæri nýstárlegum lyfjum til að koma í veg fyrir og meðhöndla lífshættulega sjúkdóma, þar á meðal HIV, veirulifrarbólgu og krabbamein. Gilead starfar í meira en 35 löndum um allan heim, með höfuðstöðvar í Foster City, Kaliforníu. Gilead Sciences keypti Kite árið 2017.
